{"filings":[{"id":1065285,"accession_number":"0001193125-26-271449","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2026-06-15T23:23:08+00:00","items":["5.07"],"status":"ready","headline":"Kyntra Bio: Michael Kauffman elected Class III director with 96% vote; exec comp, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Michael Kauffman, M.D., Ph.D., elected Class III director with 1,239,169 votes for (96.04%), 0 against, 51,081 withheld.","Advisory vote on executive compensation approved: 1,242,005 for, 23,606 against, 24,639 abstain.","Ratification of PricewaterhouseCoopers as auditor for FY 2026: 2,712,825 for, 14,392 against, 7,461 abstain.","Broker non-votes totaled 1,444,428 on director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":947639,"accession_number":"0001193125-26-264000","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2026-06-09T21:04:50+00:00","items":["8.01"],"status":"ready","headline":"Kyntra Bio receives final $4M holdback from AstraZeneca for China ops sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $4.0M from AstraZeneca, satisfying final holdback under February 2025 share purchase agreement.","Total consideration for sale of China operations was ~$220M ($85M enterprise value + ~$135M net cash).","Previously received $6.0M holdback plus $0.4M net cash adjustment payment in November 2025.","With this payment, all owed amounts under the Share Purchase Agreement have been collected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12891,"accession_number":"0001193125-26-216731","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2026-05-11T20:05:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyntra Bio reports Q1 2026 net loss of $15.1M ($3.74/share) and cash runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 2 trial of FG-3246 in mCRPC enrolling; interim analysis expected in 4Q 2026.","Positive combo data with enzalutamide: median rPFS 7.0 mo overall, 10.1 mo in 1 prior ARPI.","Pivotal Phase 3 protocol for roxadustat in LR-MDS being finalized after FDA feedback; trial start H2 2026.","Revenue $3.7M (up from $2.7M); net loss $15.1M vs $16.8M YoY.","Cash and equivalents $100.3M; sufficient to fund operations into 2028."],"consensus_eps_estimate":-3.4221,"consensus_eps_actual":-3.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":3738000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99786,"accession_number":"0001193125-26-149624","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Kyntra Bio receives Nasdaq delisting notice for failing $50M assets/revenue rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on April 2, 2026, for non-compliance with Listing Rule 5450(b)(3)(A) regarding $50M total assets and revenue.","Non-compliance due to FibroGen International revenue reclassified as discontinued operations in 2024-2025.","Company has 45 days (by May 18, 2026) to submit a plan to regain compliance; Nasdaq may grant up to 180-day extension.","Company may consider transferring to Nasdaq Capital Market as alternative."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115992,"accession_number":"0001193125-26-108324","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kyntra Bio reports FY2025 revenue $6.4M, net loss $58.2M; cash $109.4M into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full yr 2025 revenue from cont ops $6.4M (vs $29.6M in 2024); net loss $58.2M (vs $153.1M).","Cash, equivalents, investments, and receivables $109.4M as of Dec 31, 2025; runway into 2028.","Phase 2 monotherapy trial of FG-3246 in mCRPC enrolling; interim analysis expected 2H 2026.","Phase 3 protocol for roxadustat in LR-MDS anemia submitted to FDA; start targeted 2H 2026.","Combo trial of FG-3246 + enzalutamide showed median rPFS 7.0 months; data at ASCO GU 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115991,"accession_number":"0001193125-26-006327","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"FibroGen rebrands as Kyntra Bio; new ticker KYNB effective Jan 8; pipeline milestones detailed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed to Kyntra Bio, Inc. via Certificate of Amendment effective 4:30pm ET Jan 7, 2026.","Common stock to trade under symbol KYNB on Nasdaq at market open Jan 8, 2026; CUSIP unchanged.","CEO cites sale of FibroGen China, payoff of term loan, and cash runway extended into 2028.","FG-3246 Phase 2 monotherapy interim results expected H2 2026; topline Phase 1b/2 combo at ASCO GU Q1 2026.","Roxadustat granted FDA Orphan Drug Designation for MDS; pivotal Phase 3 protocol submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132406,"accession_number":"0001193125-25-274192","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FibroGen Q3 2025: Net loss $13.1M, China sale ~$220M, cash $121.1M into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $13.1M ($3.25 loss per share) vs $48.3M ($12.01 loss) YoY.","Total revenue from continuing ops $1.1M, up from $0.1M YoY.","Completed sale of FibroGen China to AstraZeneca for ~$220M ($85M enterprise + $135M net cash).","Cash, equivalents, receivables, and investments $121.1M; cash runway into 2028; repaid Morgan Stanley term loan.","Initiated Phase 2 trial of FG-3246 in mCRPC; FDA agreed on Phase 3 roxadustat design for LR-MDS."],"consensus_eps_estimate":-4.0851,"consensus_eps_actual":48.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":5163000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132405,"accession_number":"0001193125-25-269529","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FibroGen receives $6.4M holdback payment from AstraZeneca on China sale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $6.4M from AstraZeneca, satisfying $6.0M first holdback plus $0.4M net cash adjustment.","China operations sale closed Aug 29, 2025; total consideration ~$220M ($85M enterprise + ~$135M net cash).","$210M paid at closing; $4.0M second holdback for indemnity claims remains, releasable nine months post-close.","Payment marks release of first post-closing holdback under February 2025 share purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148975,"accession_number":"0000921299-25-000007","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"FibroGen completes sale of China business to AstraZeneca for ~$220M; repays $81M term loan","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sale price ~$220M: $85M enterprise value plus ~$135M net cash held in China.","Net cash received $210.4M; transaction costs $7.7M; net assets sold $138.9M.","Pro forma cash and equivalents rise to $145M from $23M; pro forma deficit narrows to $1.684B.","Repaid $80.9M to MSTV, including $73.7M term loan balance and $6.8M loss on debt extinguishment.","Released $142.9M deferred revenue related to China single performance obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148974,"accession_number":"0000950170-25-112341","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroGen completes $220M sale of China ops to AstraZeneca; cash runway extended to 2028","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration ~$220M ($85M enterprise value + ~$135M net cash), $60M above initial guidance.","Repaid ~$81M term loan to Morgan Stanley Tactical Value; cash runway now extended into 2028.","Phase 2 monotherapy trial of FG-3246 in mCRPC on track to commence in Q3 2025.","Phase 3 protocol for roxadustat in LR-MDS anemia to be submitted in Q4 2025 after positive FDA meeting.","FibroGen retains roxadustat rights in U.S. and all markets not licensed to Astellas (excl. China/South Korea)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148973,"accession_number":"0000950170-25-109571","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroGen receives China SAMR approval for sale of China business to AstraZeneca; closing expected in Q3 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["China State Administration for Market Regulation decided not to prohibit AstraZeneca's acquisition of FibroGen China.","Transaction includes all equity of FibroGen International (Hong Kong) Ltd. and roxadustat assets in China.","Closing expected in Q3 2025, subject to customary closing conditions and deliverables.","FibroGen retains roxadustat rights in US, Canada, Mexico, and other non-AstraZeneca/Astellas territories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148972,"accession_number":"0000950170-25-108280","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"FibroGen amends debt agreement, reduces minimum cash requirement from $18.75M to $15M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fourth Amendment to Financing Agreement with Morgan Stanley Tactical Value lenders executed August 12, 2025.","Minimum qualified cash balance reduced from $18.75 million to $15.0 million effective immediately.","Prior amendments dated May 8, June 5, and July 14, 2025 indicate ongoing covenant adjustments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148971,"accession_number":"0000950170-25-106534","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FibroGen Q2 loss narrows to $13.7M; China sale to AstraZeneca now ~$210M, cash runway into 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $13.7M ($3.38/sh) vs $47.1M loss ($11.79/sh) in Q2 2024; revenue $1.3M.","Sale of FibroGen China to AstraZeneca now ~$210M total consideration (up $50M), including ~$125M net cash; close expected Q3 2025.","Cash runway extended into 2028 upon China sale close; Q2 consolidated cash $142.1M.","Agreed with FDA on pivotal Phase 3 design for roxadustat in LR-MDS with high transfusion burden; protocol filing Q4 2025.","Phase 2 monotherapy trial of FG-3246 in mCRPC expected to start Q3 2025; combo data from UCSF study expected Q4 2025."],"consensus_eps_estimate":-2.3511,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":4088000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148970,"accession_number":"0000950170-25-095628","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"FibroGen reduces minimum cash covenant to $18.75M in third amendment to Morgan Stanley financing","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Third Amendment to Financing Agreement dated July 14, 2025 lowers required U.S. qualified cash from $22.5M to $18.75M.","Amendment with lenders managed by Morgan Stanley Tactical Value and agent Wilmington Trust.","Effective July 14, 2025; no other changes to Financing Agreement terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167922,"accession_number":"0000950170-25-086142","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"FibroGen terminates prior HiFiBiO license deal, licenses anti-CCR8 and anti-Gal-9 assets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Exclusive License and Option Agreement with HiFiBiO dated June 2021, as amended Feb 2024.","Licensed anti-CCR8 (FG-3175) and anti-Gal-9 (FG-3165) intellectual property to HiFiBiO.","Eligible for mid single-digit to low double-digit share of HiFiBiO's sublicense revenues and low double-digit share of commercial royalties.","If HiFiBiO commercializes either asset, FibroGen receives single-digit royalties on worldwide net sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167921,"accession_number":"0000950170-25-085439","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"FibroGen to effect 1-for-25 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 5:00 p.m. ET June 16, 2025; post-split trading begins June 17.","Outstanding shares reduced from ~101.1M to ~4.0M; new CUSIP 31572Q881.","No fractional shares issued; cash paid in lieu of fractional interests.","Split approved by stockholders at June 4, 2025 annual meeting.","Aims to meet Nasdaq minimum bid price requirement (Rule 5450(a)(1))."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167920,"accession_number":"0000950170-25-083676","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["5.07","5.02","1.01","9.01"],"status":"ready","headline":"FibroGen shareholders approve reverse stock split; appoints Michael Kauffman to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split (1:10-1:25) to meet Nasdaq listing requirement; 85% voted in favor.","Jeffrey L. Edwards re-elected as Class II director with 92.25% of votes cast.","Dr. Michael Kauffman appointed to board, will serve on Audit and Compensation Committees; term expires 2026.","Director Aoife Brennan resigned effective June 4, 2025, no disagreement with company.","Second amendment to financing agreement lowered minimum cash balance from $27M to $22.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167919,"accession_number":"0000950170-25-069159","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FibroGen Q1 net loss narrows to $16.8M; China sale consideration raised to ~$185M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue from continuing ops fell to $2.7M from $25.4M YoY; net loss improved to $16.8M ($0.16/sh) from $49.0M.","Sale of FibroGen China to AstraZeneca now expected total consideration ~$185M (enterprise $85M + net cash ~$100M); close in 3Q-2025.","Upon China sale close, cash runway extended into 2H 2027; Morgan Stanley term loan to be repaid.","Phase 2 monotherapy trial of FG-3246 (CD46 ADC) in mCRPC expected to start 3Q-2025; topline combo data from UCSF study due 4Q-2025.","Filed Type-C meeting request with FDA for roxadustat in LR-MDS anemia; feedback expected in 3Q-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":2739000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167918,"accession_number":"0000950170-25-051219","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"FibroGen amends bylaws to lower stockholder quorum to one-third from majority","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Amended and Restated Bylaws effective April 2, 2025.","Quorum reduced to holders of at least one-third of outstanding shares, down from majority.","Separate class quorum also changed to one-third of voting power.","Amendment applies to all stockholder meetings; no other bylaw changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185161,"accession_number":"0000950170-25-046978","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FibroGen publishes Phase 1 FG-3246 mCRPC data in JCO; ORR 20%, DCR 80%, mid-2025 Phase 2 start","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 study of FG-3246 (anti-CD46 ADC) in mCRPC published in Journal of Clinical Oncology.","Confirmed ORR 20%, DCR 80%, median rPFS 8.7 months in evaluable patients.","PSA50 response rate 36% in 39 evaluable patients; half of docetaxel-sensitive patients responded.","Safety profile consistent with MMAE ADCs; ocular AEs infrequent; MTD 2.7 mg/kg every 3 weeks.","Phase 2 monotherapy dose optimization to start by mid-2025; combo enzalutamide topline in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185160,"accession_number":"0000950170-25-046948","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"FibroGen and Fortis amend agreements, extend option exercise deadline to Dec 31, 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendments No.1 to Evaluation Agreement and Option Agreement & Plan of Merger executed March 28, 2025.","Original agreements dated June 6, 2024, as amended and restated from May 5, 2023.","Option exercise deadline under both agreements extended to December 31, 2027.","Full text of amendments to be filed with FibroGen's Q1 2025 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185159,"accession_number":"0000950170-25-040248","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"FibroGen gets Nasdaq delisting notice; appeals; reports Q4 loss of $8.7M, China sale to AstraZeneca","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified FibroGen on March 12, 2025 that it failed to regain $1.00 minimum bid price; delisting stayed after March 14 appeal; hearing pending.","Q4 2024 revenue from continuing ops $3.1M (vs $3.6M Q4 2023); net loss $8.7M ($0.08 loss per share) vs $62.5M ($0.63) prior year.","Full year 2024 net loss from continuing ops $153.1M ($1.53 loss/share) vs $323.0M ($3.32) in 2023; total cash $121.1M at year-end.","Announced sale of FibroGen China to AstraZeneca for ~$160M; expected close by mid-2025; proceeds to repay term loan, extend cash runway into 2027.","Upcoming milestones: Phase 2 monotherapy trial of FG-3246 in mCRPC start by mid-2025; topline combo study results 2H 2025; FDA meeting for roxadustat in LR-MDS in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185158,"accession_number":"0001193125-25-033539","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"FibroGen enters ATM equity offering agreement for up to $30M with BofA Securities","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May sell up to $30M of common stock from time to time through BofA as sales agent.","BofA will receive a commission of up to 3.0% of gross sales proceeds.","Company is not obligated to sell any shares; offering may terminate upon sale of all shares or by agreement.","Shares sold under effective shelf registration (333-280597) and prospectus supplement dated Feb 24, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":185157,"accession_number":"0000950170-25-023729","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["1.01","2.02","5.02","7.01","9.01"],"status":"ready","headline":"FibroGen sells China ops to AstraZeneca for ~$160M; cash runway to 2027","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price: $85M enterprise value plus net China cash (~$75M) for total ~$160M.","Transaction expected to close by mid-2025, subject to China regulatory approval.","Proceeds will repay ~$80M term loan to Morgan Stanley Tactical Value; cash runway extended into 2027.","Upon close, AstraZeneca gets full roxadustat rights in China; FibroGen retains U.S. and ex-AstraZeneca markets.","Senior VP China Operations Christine Chung will depart upon closing; Phase 2 trial of FG-3246 in mCRPC expected 2Q 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201762,"accession_number":"0000950170-24-136408","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"FibroGen appoints David DeLucia as CFO effective Dec 16, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David DeLucia, previously VP of FP&A and IR, promoted to CFO, succeeding Juan Graham who stepped down Dec 15.","DeLucia has nearly 15 years life sciences finance experience; previously at TherapeuticsMD and JP Morgan Asset Mgmt.","As CFO, DeLucia will oversee finance, treasury, IR; reports to CEO Thane Wettig.","Severance terms include 9 months salary for ordinary termination; 12 months salary plus bonus & equity vesting for CIC termination.","Company highlights advancing FG-3246 ADC and companion diagnostic FG-3180 alongside roxadustat performance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201761,"accession_number":"0000950170-24-125332","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FibroGen Q3 revenue up 15% to $46.3M; net loss narrows to $17.1M; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue from roxadustat in China $46.2M, +57% YoY; total roxadustat net sales $96.6M, +25% YoY.","Net loss $17.1M ($0.17 loss per share) vs $63.6M ($0.65) YoY; cash & equivalents $160M sufficient into 2026.","Full-year guidance: total roxadustat net sales $330-350M; net product revenue $135-150M; cost plan substantially complete by year-end.","Pamrevlumab trials in pancreatic cancer (mPDAC and LAPC) failed primary endpoints; pipeline focus shifts to FG-3246 ADC.","FG-3246 Phase 2 combo study results expected 1H 2025; Phase 2 monotherapy trial starts Q1 2025; CIA approval decision early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":152877000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201760,"accession_number":"0000950170-24-112331","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"FibroGen terminates headquarters lease, accelerates expiration to Dec 31, 2024, with $10M settlement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Lease Termination Agreement with landlord ARE-San Francisco No.43 Owner, LLC.","Lease at 409 Illinois Street, San Francisco, ends Dec 31, 2024 (previously later date).","$10M settlement includes past rent, operating costs, lease modification payment, and security deposit (LC).","FibroGen not responsible for further rent or operating costs after termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217765,"accession_number":"0000950170-24-106818","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-09-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"FibroGen receives Nasdaq delisting notice over bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified FibroGen on Sept 12 that its stock closed below $1.00 for 30 consecutive days, triggering potential delisting.","FibroGen has 180 days, until March 11, 2025, to regain compliance by achieving a closing bid of at least $1.00 for ten consecutive business days.","If not compliant by March 11, FibroGen may seek an additional 180-day period if it meets other listing requirements and intends to cure, e.g., via reverse stock split.","FibroGen currently meets all other Nasdaq continued listing standards except the bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217764,"accession_number":"0000950170-24-106359","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"FibroGen directors Blaug, Cravatt, Lema resign effective Sept 30; committees reassigned","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Suzanne Blaug, Benjamin Cravatt, and Gerald Lema resign from the Board effective September 30, 2024.","Resignations are not due to any disagreement with the Company or its management.","Audit Committee now comprises Jeffrey L. Edwards (Chair), Maykin Ho, and James A. Schoeneck.","Compensation Committee: James A. Schoeneck (Chair) and Aoife Brennan; Nominating Committee: James A. Schoeneck (Chair) and Jeffrey L. Edwards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217763,"accession_number":"0000950170-24-104395","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"FibroGen terminates CFO Juan Graham and CMO Deyaa Adib as part of cost reduction plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Juan Graham and CMO Deyaa Adib given termination notice on Aug 30, 2024.","Graham's departure date: Dec 15, 2024; Adib's departure date: Nov 1, 2024.","Terminations are part of a cost reduction plan initiated Aug 2, 2024.","Company states decisions not due to any disagreement with executives.","Both will remain through transition periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217762,"accession_number":"0000950170-24-092967","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"FibroGen cuts 75% of U.S. workforce (127 employees); charges $16-18M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~75% (127 U.S. employees) effective Aug 2, 2024.","Estimated non-recurring charges of $16-18M for severance, payroll, benefits.","Majority of charges expected in H2 2024; cash payments substantially complete by Q1 2025.","Restructuring follows negative pamrevlumab clinical trial data announced earlier that week.","Potential position eliminations subject to legal requirements; process may extend beyond Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217761,"accession_number":"0000950170-24-091766","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FibroGen Q2 net revenue +14% to $50.6M; cuts US workforce 75% after pancreatic trial failures","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $15.5M ($0.16/sh) from $87.7M ($0.90) YoY; revenue $50.6M (+14%).","Raising 2024 roxadustat net product revenue guidance to $135-150M; China total net sales $92.3M (+21%).","U.S. workforce cut ~75% after pamrevlumab misses endpoints in pancreatic cancer trials (PanCAN, LAPIS).","Focusing on FG-3246 ADC for mCRPC; Phase 2 combo topline expected 1H 2025, monotherapy study start 1Q 2025.","Cash, equivalents and AR $147.1M; runway into 2026; CIA approval in China 2H 2024 could trigger $10M milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":106544000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237669,"accession_number":"0000950170-24-077616","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroGen hosts KOL event on FG-3246 for metastatic castration-resistant prostate cancer","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["June 26, 2024: FibroGen and UCSF's Dr. Rahul Aggarwal presented on FG-3246 development program for mCRPC.","Presentation covers unmet need, evolving treatment landscape, and clinical development plans for FG-3246.","No financial results or new clinical data disclosed in the filing or the included exhibit.","Forward-looking statements caution that FG-3246 program involves substantial risks and uncertainties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237668,"accession_number":"0000950170-24-070636","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"FibroGen stockholders approve 2024 Equity Incentive Plan and elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I directors elected: Thane Wettig (54.9M for), James Schoeneck (53.1M for), Maykin Ho (53.6M for).","2024 Equity Incentive Plan approved: 44.3M for, 10.8M against; plan adds 2.2M new shares plus prior plan reserve.","Advisory vote on executive compensation approved: 53.5M for, 1.75M against.","PricewaterhouseCoopers ratified as independent auditor for 2024: 72.5M for, 0.2M against.","Say-on-pay frequency: every year preferred (54.8M votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237667,"accession_number":"0000950170-24-053533","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FibroGen Q1 2024 revenue up 55% YoY to $55.9M; net loss narrows to $32.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.9M ($0.33 per share) vs $76.7M loss ($0.81 per share) in Q1 2023.","Roxadustat China net sales by FibroGen and JDE totaled $79.4M, up 24% YoY on 39% volume growth.","Topline data for pamrevlumab in metastatic pancreatic cancer expected mid-2024; LAPIS Phase 3 data in 3Q 2024.","Phase 1 FG-3246 (CD46 ADC) in mCRPC showed median rPFS of 8.7 months; 20% partial response rate.","Cash and receivables $214.7M; runway into 2026; FY 2024 roxadustat revenue guidance reaffirmed $120-135M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":55902000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":255191,"accession_number":"0000950170-24-020146","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FibroGen FY23 rev $147.8M (+5% YoY), net loss $284.2M; guides China roxadustat $300-340M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 total revenue $147.8M, up 5% YoY; net loss $284.2M ($2.92 per share), narrower than $293.7M loss in 2022.","Roxadustat net sales in China (FibroGen share) $100.9M in FY23, up 22% YoY; total China sales including JDE $284.1M (+36% YoY) driven by 41% volume growth.","Cash and equivalents $248.1M, with runway into 2026 after $120M annual cost reduction.","Pipeline: topline data from two pamrevlumab pancreatic cancer trials expected in 2Q 2024; Phase 1 FG-3246 data in mCRPC in 1Q 2024.","Guidance: FY 2024 FibroGen net product revenue $120-135M; total roxadustat China sales $300-340M; potential CIA approval in China mid-2024 with $10M milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":147752000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272650,"accession_number":"0000950170-23-059381","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FibroGen Q3 revenue up 155% to $40.1M; roxadustat China sales up 31%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $63.6M ($0.65 loss per share) vs $91.7M ($0.98) YoY; restructuring charge of $12.6M.","Roxadustat net product revenue in China reached $29.4M, up 69% YoY; total China sales $77.1M (up 31%), driven by 37% volume growth.","Annualized cost reduction of $120M implemented; cash of $283.0M expected to fund operations into 2026.","Pamrevlumab LAPIS Phase 3 topline data expected Q1 2024; PanCAN Phase 2/3 data in 1H 2024.","sNDA for roxadustat in chemotherapy-induced anemia accepted in China; approval decision mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":120614000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272649,"accession_number":"0000950170-23-056018","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"FibroGen receives Nasdaq notice of non-compliance for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Closing bid price of FGEN stock below $1.00 for 30 consecutive business days as of Oct 24, 2023.","Company has 180 calendar days (until April 22, 2024) to regain compliance.","To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.","If not cured, FibroGen may qualify for an additional 180-day period if other listing standards met.","FibroGen states it meets all other Nasdaq continued listing requirements except bid price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272648,"accession_number":"0000950170-23-052242","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"FibroGen appoints Thane Wettig as permanent CEO and Board member, effective Oct 2, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thane Wettig promoted from Interim CEO to CEO and Board member as of Oct 2, 2023.","Mr. Wettig had served as Interim CEO since July 23, 2023.","Appointed as Class I director with term expiring at 2024 annual meeting.","Compensation terms remain per prior 8-K filed July 25, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289499,"accession_number":"0000950170-23-046574","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-09-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"FibroGen CMO Mark Eisner resigns; search underway for replacement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CMO Mark Eisner resigns effective Sept 8, 2023; departure voluntary with no disagreement.","Eisner to serve as consultant through Oct 11, 2023 at $15K/month; equity awards continue vesting.","Company has initiated search for a new Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289498,"accession_number":"0000950170-23-045111","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-08-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroGen Phase 3 pamrevlumab trial for DMD fails to meet primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint (NSAA total score change at week 52) not met: mean difference -0.528 points (p=0.5553).","All secondary endpoints including stair climb velocity and 10-meter walk/run test also not met.","Pamrevlumab was generally safe and well tolerated; SAEs 8.3% pamrevlumab vs 2.8% placebo.","Company evaluating total data and will share full results at a future medical forum.","Interim CEO Thane Wettig expressed disappointment and gratitude to trial participants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289497,"accession_number":"0000950170-23-039052","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FibroGen Q2 revenue up 49% but net loss widens; multiple Phase 3 failures; new CEO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $44.3M (+49% YoY); net loss $87.7M ($0.90) vs $72.6M ($0.78) last year; includes $24.6M one-time charge.","Reported negative topline from three Phase 3 trials: MATTERHORN (roxadustat MDS), LELANTOS-1 (pamrevlumab DMD), ZEPHYRUS-1 (pamrevlumab IPF); ZEPHYRUS-2 discontinued.","China roxadustat net sales $76.4M (+44% YoY) driven by >40% volume growth; number one anemia brand in China.","Appointed Thane Wettig as Interim CEO; implemented cost reduction plan targeting $100-120M annualized GAAP expense savings.","Exclusive license for FOR46 (FG-3246) ADC targeting CD46 for mCRPC; $75M non-dilutive term loan from Morgan Stanley."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":80480000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289496,"accession_number":"0000950170-23-034234","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"FibroGen appoints Thane Wettig as Interim CEO; Enrique Conterno resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thane Wettig, previously Chief Commercial Officer, named Interim CEO effective July 23, 2023.","Enrique Conterno resigned as CEO and from the Board; will serve as Special Advisor through August 8, 2023.","Conterno's resignation not due to any disagreement with the company.","Wettig receives monthly $10,000 stipend on $545,000 base salary; bonus target rises to 75% of base as Interim CEO.","Conterno entered consulting agreement at $35,000 per month through September 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289495,"accession_number":"0000950170-23-033458","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"FibroGen cuts US workforce 32% (104 employees); expects $13-15M charges","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~32% (104 U.S. employees) approved July 14, 2023.","Non-recurring charges of $13-15M for severance, notice pay, vacation, benefits.","Plan expected to generate $30-35M in annual cost savings.","Majority of charges in Q3 2023; reduction substantially complete by Q1 2024.","Company expects existing cash, equivalents, investments to fund ops into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310330,"accession_number":"0000950170-23-029736","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroGen Phase 3 ZEPHYRUS-1 trial of pamrevlumab for IPF fails primary endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 ZEPHYRUS-1 did not meet primary endpoint: change in FVC at week 48 (p=0.29); placebo-corrected difference 70 ml.","Secondary endpoint (disease progression or death) also not met (HR=0.78, 95% CI 0.52-1.15).","ZEPHYRUS-2 Phase 3 IPF trial will be discontinued based on these results.","Company plans cost reductions to extend cash runway into 2026; roxadustat commercialization continues.","Upcoming milestones: DMD data 3Q 2023, pancreatic cancer data 1H 2024, new IND filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310329,"accession_number":"0000950170-23-027252","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"FibroGen shareholders elect Class III directors, approve say-on-pay and auditor ratification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrique Conterno, Aoife Brennan, and Gerald Lema elected as Class III directors with 67.4M, 69.2M, and 67.6M votes for, respectively.","Advisory vote on executive compensation passed: 48.7M for, 21.9M against, 89K abstain (31% opposed).","Ratification of PricewaterhouseCoopers as auditor for 2023: 78.5M for, 674K against, 2.2M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310328,"accession_number":"0000950170-23-026748","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroGen's pamrevlumab fails Phase 3 DMD study in non-ambulatory patients; primary endpoint not met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 LELANTOS-1 study of pamrevlumab in non-ambulatory DMD patients did not meet primary endpoint (PUL 2.0 score at week 52).","Pamrevlumab was generally safe and well tolerated; most adverse events were mild or moderate.","Topline results from LELANTOS-2 Phase 3 study in ambulatory DMD patients expected in Q3 2023.","CEO Enrique Conterno expressed disappointment and thanked patients, caregivers, and investigators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310327,"accession_number":"0000950170-23-022879","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-05-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FibroGen announces positive Phase 3 results for roxadustat in chemotherapy-induced anemia in China","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Met primary endpoint: noninferiority to erythropoietin alfa in hemoglobin change from baseline to average weeks 9-13.","Plan to file supplemental New Drug Application in China with AstraZeneca collaboration.","159 non-myeloid malignancy patients enrolled; roxadustat dosed three times weekly for 12 weeks.","Adverse event profile consistent with prior studies, supporting positive benefit-risk.","Detailed results to be presented at an upcoming medical conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310326,"accession_number":"0000950170-23-018795","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"FibroGen Q1 loss $0.81; China roxadustat sales up 47%; pamrevlumab Ph3 data expected in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $76.7M ($0.81/sh) vs $63.2M ($0.68/sh) in Q1 2022.","Total revenue $36.2M, down from $60.8M (prior year included $25M milestone).","China roxadustat net product revenue $24.2M (+28% YoY); total China sales $64.1M (+47%).","Completed non-dilutive term loan facility of up to $150M with Morgan Stanley Tactical Value.","Topline data from four Phase 3 trials (pamrevlumab in DMD, IPF, LAPC; roxadustat in CIA) expected through 3Q 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":36161000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":310325,"accession_number":"0000950170-23-016300","cik":921299,"company_name":"KYNTRA BIO, INC.","ticker":"KYNB","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"FibroGen enters $75M senior secured term loan with Morgan Stanley Tactical Value; up to $150M total","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Initial $75M term loan funded by May 8, 2023; additional $37.5M milestone-based loan and $37.5M discretionary loan available.","Interest rate 14.0% per annum payable monthly; maturity May 8, 2026; no amortization payments.","Minimum $30M unrestricted cash and cash equivalents covenant tested monthly.","Loans secured by substantially all assets; guarantees from subsidiaries excluding Chinese subsidiary.","Prepayment requires make-whole amount including remaining scheduled interest to maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28701113.95863053,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-05-01T23:59:59+00:00|310325"}